Vaughan David Investments LLC IL Increases Position in CVS Health Co. (NYSE:CVS)

Vaughan David Investments LLC IL boosted its holdings in CVS Health Co. (NYSE:CVS) by 5.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 398,486 shares of the pharmacy operator’s stock after acquiring an additional 19,188 shares during the period. Vaughan David Investments LLC IL’s holdings in CVS Health were worth $23,535,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of CVS Health during the 4th quarter worth about $1,092,040,000. Capital International Investors boosted its position in shares of CVS Health by 47.4% in the fourth quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock worth $2,660,298,000 after acquiring an additional 10,837,801 shares during the last quarter. Pzena Investment Management LLC boosted its position in shares of CVS Health by 132.9% in the second quarter. Pzena Investment Management LLC now owns 12,936,388 shares of the pharmacy operator’s stock worth $764,023,000 after acquiring an additional 7,382,931 shares during the last quarter. Capital World Investors boosted its position in shares of CVS Health by 8.0% in the first quarter. Capital World Investors now owns 43,776,874 shares of the pharmacy operator’s stock worth $3,491,643,000 after acquiring an additional 3,232,172 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of CVS Health by 306.6% in the fourth quarter. Clearbridge Investments LLC now owns 3,046,216 shares of the pharmacy operator’s stock worth $240,529,000 after acquiring an additional 2,297,100 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of CVS opened at $56.94 on Wednesday. CVS Health Co. has a 1 year low of $52.77 and a 1 year high of $83.25. The company has a market cap of $71.48 billion, a price-to-earnings ratio of 10.01, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.66 and a current ratio of 0.86. The firm has a fifty day moving average of $58.25 and a 200-day moving average of $63.39.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.10. CVS Health had a net margin of 1.98% and a return on equity of 12.72%. The business had revenue of $91.23 billion for the quarter, compared to analysts’ expectations of $91.41 billion. During the same period in the previous year, the business earned $2.21 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. As a group, equities analysts anticipate that CVS Health Co. will post 6.51 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Monday, July 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.67%. The ex-dividend date of this dividend was Monday, July 22nd. CVS Health’s dividend payout ratio (DPR) is presently 46.75%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CVS shares. Baird R W raised shares of CVS Health to a “hold” rating in a research report on Thursday, May 30th. JPMorgan Chase & Co. decreased their target price on shares of CVS Health from $101.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Barclays cut their price target on shares of CVS Health from $65.00 to $63.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $62.00 price target on shares of CVS Health in a report on Tuesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $68.00 price target on shares of CVS Health in a report on Wednesday, September 4th. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.48.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.